Compare Vanguard S&P 500 Growth Index Fund ETF (VOOG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 Growth Index Fund ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard S&P 500 Growth Index Fund ETF trades at $85.14, while Vertex Pharmaceuticals Incorporated trades at $528 (market cap $134.25B). Which is the better fit depends on your goals.
| VOOG | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $85.42 | $529.65 |
52-Week Low | $65.32 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOOG, the Vanguard S&P 500 Growth ETF, trades at $85.42, up 0.68% on the day and near a 52-week high. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI suggests overbought conditions. Recent news highlights institutional accumulation, such as Apella Capital increasing its stake by 463.2% in Q2 2026, and positive coverage from financial outlets comparing its low expense ratio and growth focus favorably against peers.
The outlook for VOOG remains positive, driven by exposure to large-cap growth stocks and strong institutional interest. Key risks include high concentration in technology sectors, making it vulnerable to sector-specific downturns, and broader market volatility. Its low expense ratio of 0.07% and historical outperformance present a compelling case for growth-oriented investors, but caution is warranted given elevated valuations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
